Cargando…

Any possible role of phosphodiesterase type 5 inhibitors in the treatment of severe COVID19 infections? A lesson from urology

Detalles Bibliográficos
Autores principales:	Dal Moro, Fabrizio, Livi, Ugolino
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136948/ https://www.ncbi.nlm.nih.gov/pubmed/32272196 http://dx.doi.org/10.1016/j.clim.2020.108414

Ejemplares similares

The war against the SARS-CoV2 infection: Is it better to fight or mitigate it?
por: Dal Moro, Fabrizio, et al.
Publicado: (2020)

Clinical and preclinical treatment of urologic diseases with phosphodiesterase isoenzymes 5 inhibitors: an update
por: Zhang, Wen-Hao, et al.
Publicado: (2016)

Online Survey on Twitter: A Urological Experience
por: Dal Moro, Fabrizio
Publicado: (2013)

Analysis of Prescriptions of Alpha-Blockers and Phosphodiesterase 5 Inhibitors from the Urology Department and Other Departments
por: Kang, Dong Hyuk, et al.
Publicado: (2011)

Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors
por: Al-Ameri, H, et al.
Publicado: (2009)

AB030. Evolution of phosphodiesterase type 5 inhibitors
por: Moon, Du Geon
Publicado: (2016)

COVID-19 and Phosphodiesterase Enzyme Type 5 Inhibitors
por: Al-Kuraishy, Hayder M., et al.
Publicado: (2020)

Evolution of Phosphodiesterase-5 Inhibitors
por: Moon, Du Geon
Publicado: (2015)

Nomograms in Urologic Oncology: Lights and Shadows
por: Morlacco, Alessandro, et al.
Publicado: (2021)

Identification of cytosolic phosphodiesterases in the erythrocyte: A possible role for PDE5
por: Adderley, Shaquria P., et al.
Publicado: (2011)

Tissue Engineering and Regenerative Medicine in Pediatric Urology: Urethral and Urinary Bladder Reconstruction
por: Casarin, Martina, et al.
Publicado: (2022)

Frailty and elderly in urology: Is there an impact on post-operative complications?
por: Dal Moro, Fabrizio, et al.
Publicado: (2017)

Urology: a trip into metaverse
por: Randazzo, Gianmarco, et al.
Publicado: (2023)

Determination of Phosphodiesterase Type-5 Inhibitors (PDE-5) in Dietary Supplements
por: Gheorghiu, Oana Ramona Cătălina, et al.
Publicado: (2023)

Phosphodiesterase type 5 inhibitors: Irrational use in Saudi Arabia
por: Alshahrani, Saad, et al.
Publicado: (2016)

Phosphodiesterase Type 5 Inhibitors and sudden sensorineural hearing loss
por: Barreto, Monique Antunes de Souza Chelminski, et al.
Publicado: (2015)

The role of phosphodiesterase-5 inhibitors in prostatic inflammation: a review
por: Peixoto, Christina Alves, et al.
Publicado: (2015)

Repurposing phosphodiesterase-5 inhibitors as chemoadjuvants
por: Tiwari, Amit K., et al.
Publicado: (2013)

Combination phosphodiesterase type 4 inhibitor and phosphodiesterase type 5 inhibitor treatment reduces non-voiding contraction in a rat model of overactive bladder
por: Balog, Brian M., et al.
Publicado: (2019)

Lipoxin A4 as a possible mediator of the beneficial actions of phosphodiesterase-5 enzyme inhibitors
por: Das, Undurti N.
Publicado: (2016)

A role for phosphodiesterase type 5 inhibitors in remodelling the urinary bladder after radiation exposure
por: Kim, Hee Youn, et al.
Publicado: (2020)

Counterfeit phosphodiesterase type 5 inhibitors pose significant safety risks
por: Jackson, G, et al.
Publicado: (2010)

Chronic Low Dosing of Phosphodiesterase Type 5 Inhibitor for Erectile Dysfunction
por: Sung, Hyun Hwan, et al.
Publicado: (2012)

Phosphodiesterase type 5 inhibitors: back and forward from cardiac indications
por: Corinaldesi, C., et al.
Publicado: (2015)

Revisiting the halogen bonding between phosphodiesterase type 5 and its inhibitors
por: Jedwabny, Wiktoria, et al.
Publicado: (2019)

Phosphodiesterase Type 5 Inhibitors and COVID-19: Are They Useful In Disease Management?
por: Mondaini, Nicola
Publicado: (2020)

Peyronie's Disease: Evolving Surgical Management and the Role of Phosphodiesterase 5 Inhibitors
por: Al-Shaiji, Tariq F., et al.
Publicado: (2009)

Phosphodiesterase-5 inhibitors for colon cancer chemoprevention
por: Islam, Bianca N., et al.
Publicado: (2018)

Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection?
por: Hutchings, David Charles, et al.
Publicado: (2018)

Phosphodiesterase-5 inhibitors: Emerging nephroprotective drugs
por: Abassi, Zaid, et al.
Publicado: (2015)

Treating diabetes with combination of phosphodiesterase 5 inhibitors and hydroxychloroquine—a possible prevention strategy for COVID-19?
por: Kukreja, Rakesh C., et al.
Publicado: (2022)

The Effect of Phosphodiesterase-type 5 Inhibitors on Erectile Function: An Overview of Systematic Reviews
por: Pyrgidis, Nikolaos, et al.
Publicado: (2021)

Phosphodiesterase Type 5 Inhibitors and Visual Side Effects: A Narrative Review
por: Barroso, Francisco, et al.
Publicado: (2021)

Are phosphodiesterase Type 5 inhibitors potential therapies for Alzheimer’s disease and related dementias?
por: Newby, Danielle
Publicado: (2022)

The role of lysyl oxidase-like 1 and fibulin-5 in the development of atherosclerosis and pelvic organ prolapse
por: Dal Moro, Fabrizio
Publicado: (2013)

The Wonders of Phosphodiesterase-5 Inhibitors: A Majestic History
por: Elhwuegi, AS
Publicado: (2016)

The first‐generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue
por: Zucchi, A., et al.
Publicado: (2019)

Upregulation of Phosphodiesterase type 5 in the Hyperplastic Prostate
por: Zhang, Wenhao, et al.
Publicado: (2015)

Phosphodiesterase type 5 and cancers: progress and challenges
por: Barone, Ines, et al.
Publicado: (2017)

Usage and perceptions of phosphodiesterase type 5 inhibitors among the male partners of infertile couples
por: Song, Seung-Hun, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_p8a8p10mu24s8k6hkmgo97k91e